Is Armata Pharmaceuticals (ARMP) Stock Halal?
Compliance Status
Not Halal
Screened on Nov 13, 2026 · AAOIFI Standard 21
Non-Compliant
Is Armata Pharmaceuticals, Inc. (ARMP) halal? Not Halal. Based on AAOIFI screening, Armata Pharmaceuticals, Inc. passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).
Quote this verdict
HalalScreener rates Armata Pharmaceuticals, Inc. (ARMP) Not Halal, 0/100, grade F under AAOIFI Standard 21, screened Nov 13, 2026. Source: https://halalscreener.app/en/stock/ARMP
Business activity
What the company sells is permissible.
Company debt
Within the limitHow much the company borrows, compared to its total value. AAOIFI allows up to 30%.
The verdict above is final and free.
Pro members can verify every number behind it: interest-bearing deposits, prohibited income breakdown, and the full AAOIFI math.
Screened according to AAOIFI Standard 21
What this means for you
Most scholars advise not holding ARMP
It does not pass AAOIFI Shariah screening.
See halal alternatives from the same sector further down this page
Share this verdict
A receipt-style image with the math on it, so whoever you send it to can check it.

ARMP
Armata Pharmaceuticals, Inc.
$3.72
-4.37%
Market Cap: 138.3M
Get an email if ARMP's halal status changes
We re-screen Armata Pharmaceuticals, Inc. daily. If the verdict moves, you hear about it the same day.
Free. One click sets it up, and you can unsubscribe any time.
About Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
Sector: Healthcare · Industry: Biotechnology
Why this does not pass
- Income from prohibited sources is over the 5% limit.
Screened under AAOIFI Standard 21. The exact figure behind this is part of Pro; the failing check and its limit are always free.
Shariah Compliance Status
Compliance History
Not Halal, unchanged since Aug 2026.
No status changes recorded since we began tracking.
Tracked since Aug 2026. Updates automatically on each re-screen.
Halal Alternatives in Healthcare
This stock is not Shariah-compliant. Here are halal alternatives from the same sector, ranked by compliance score:
More Healthcare Stocks
Know the day ARMP's verdict changes
A free account keeps watch on 3 stocks and emails you when a verdict moves. You also get 3 questions for the AI Scholar. No card needed.
Frequently Asked Questions
Is Armata Pharmaceuticals, Inc. (ARMP) halal to invest in?
Why did Armata Pharmaceuticals, Inc. get a F compliance rating?
What could change Armata Pharmaceuticals, Inc.'s Shariah verdict?
How often is Armata Pharmaceuticals, Inc. re-screened for Shariah compliance?
Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.
Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.
